(Total Views: 424)
Posted On: 07/19/2021 12:15:48 PM
Post# of 573

$CLSN News Article - Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer https://marketwirenews.com/news-releases/cels...09541.html


My Twitter: WhyteStocks